NYSE: PTN - Palatin Technologies, Inc.

Yield per half year: -79.47%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Palatin Technologies, Inc.


About Palatin Technologies, Inc.

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases.

more details
In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a peptide mimetic molecule with amino acid mimetic structure and amino acids properties; and L8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.

IPO date 1993-10-28
ISIN US6960775020
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://palatin.com
Цена ао 0.7218
Change price per day: 0% (0.2053)
Change price per week: -53.55% (0.442)
Change price per month: -74.66% (0.8101)
Change price per 3 month: -80.99% (1.08)
Change price per half year: -79.47% (1)
Change price per year: -89.19% (1.9)
Change price per 3 year: -54.38% (0.45)
Change price per 5 year: -48.68% (0.4)
Change price per year to date: -76.01% (0.8559)

Underestimation

Title Value Grade
P/S 5.96 2
P/BV -239.91 0
P/E 0 0
EV/EBITDA -0.6135 0
Total: 4

Efficiency

Title Value Grade
ROA, % -207.35 0
ROE, % -263431.19 0
Total: 1.67

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0.0071

Debt

Title Value Grade
Debt/EBITDA -0.0203 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 3705.16 10
Yield Ebitda, % 23.01 4
Yield EPS, % -10.08 0
Total: 4



Head Job title Payment Year of birth
Dr. Carl Spana Ph.D. Co-Founder, President, CEO & Director 979k 1962 (63 years)
Mr. Stephen T. Wills CPA, MST CFO, COO, Executive VP, Treasurer & Secretary 910.55k 1957 (68 years)
Burns McClellan Vice President of Investor Relations N/A
Mr. Stephen A. Slusher Esq. Chief Legal Officer N/A
Dr. Michael B. Raizman M.D. Chief Medical Officer N/A
Mr. James E. Hattersley Senior Vice President of Business Development N/A 1960 (65 years)
Mr. John Dodd Ph.D. Senior Vice President of Preclinical Development N/A
Mr. Robert Jordan Senior Vice President of Program Operations N/A

Address: United States, Cranbury. NJ, Cedar Brook Corporate Center - open in Google maps, open in Yandex maps
Website: https://palatin.com